1.4M XNYS Volume
XNYS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 170.00 per share. | 17 Mar 2025 | 4,643 | 38,117 (0%) | 0% | 170 | 789,310 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 174.13 per share. | 05 Mar 2025 | 5,370 | 68,068 (0%) | 0% | 174.1 | 935,078 | Common Stock |
| Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 04 Mar 2025 | 13,884 | 34,061 (0%) | 0% | 173.7 | 2,412,206 | Common Stock |
| Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 04 Mar 2025 | 7,684 | 26,377 (0%) | 0% | 173.7 | 1,335,018 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 04 Mar 2025 | 5,317 | 11,300 (0%) | 0% | 173.7 | 923,776 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 04 Mar 2025 | 1,823 | 9,477 (0%) | 0% | 173.7 | 316,728 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 03 Mar 2025 | 8,549 | 46,666 (0%) | 0% | 173.7 | 1,485,303 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 3,906 | 42,760 (0%) | 0% | 173.7 | 678,628 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 322 | 38,709 (0%) | 0% | 173.7 | 55,944 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 175.79 per share. | 03 Mar 2025 | 592 | 38,117 (0%) | 0% | 175.8 | 104,068 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 2,280 | 21,150 (0%) | 0% | 173.7 | 396,127 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 03 Mar 2025 | 5,674 | 23,430 (0%) | 0% | 173.7 | 985,801 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 106 | 17,756 (0%) | 0% | 173.7 | 18,416 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 5,010 | 73,438 (0%) | 0% | 173.7 | 870,437 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 03 Mar 2025 | 10,380 | 78,448 (0%) | 0% | 173.7 | 1,803,421 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 175.79 per share. | 03 Mar 2025 | 716 | 68,068 (0%) | 0% | 175.8 | 125,866 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 394 | 68,784 (0%) | 0% | 173.7 | 68,454 | Common Stock |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 1,662 | 136,553 (0%) | 0% | 173.7 | 288,756 | Common Stock |
| James E. Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 03 Mar 2025 | 61,917 | 198,470 (0%) | 0% | 173.7 | 10,757,460 | Common Stock |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 31,656 | 166,814 (0%) | 0% | 173.7 | 5,499,913 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 03 Mar 2025 | 1,711 | 35,232 (0%) | 0% | 173.7 | 297,269 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 1,692 | 33,521 (0%) | 0% | 173.7 | 293,968 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 867 | 34,365 (0%) | 0% | 173.7 | 150,633 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 992 | 10,564 (0%) | 0% | 173.7 | 172,350 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 173.74 per share. | 03 Mar 2025 | 1,879 | 13,119 (0%) | 0% | 173.7 | 326,457 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 173.74 per share. | 03 Mar 2025 | 4,434 | 14,998 (0%) | 0% | 173.7 | 770,363 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 172.61 per share. | 26 Feb 2025 | 528 | 39,031 (0%) | 0% | 172.6 | 91,138 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 286 | 39,559 (0%) | 0% | 171.8 | 49,121 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 229 | 17,853 (0%) | 0% | 171.8 | 39,331 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 455 | 70,002 (0%) | 0% | 171.7 | 78,146 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 172.61 per share. | 26 Feb 2025 | 824 | 69,178 (0%) | 0% | 172.6 | 142,231 | Common Stock |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 2,966 | 138,215 (0%) | 0% | 171.8 | 509,411 | Common Stock |
| Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 869 | 20,177 (0%) | 0% | 171.8 | 149,251 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 88 | 35,212 (0%) | 0% | 171.8 | 15,114 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 214 | 5,983 (0%) | 0% | 171.8 | 36,755 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 171.75 per share. | 26 Feb 2025 | 233 | 11,546 (0%) | 0% | 171.8 | 40,018 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 169.71 per share. | 19 Feb 2025 | 374 | 40,449 (0%) | 0% | 169.7 | 63,472 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 170.99 per share. | 19 Feb 2025 | 604 | 39,845 (0%) | 0% | 171.0 | 103,278 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Sale of securities on an exchange or to another person at price $ 169.71 per share. | 19 Feb 2025 | 320 | 18,082 (0%) | 0% | 169.7 | 54,307 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 170.99 per share. | 19 Feb 2025 | 899 | 70,457 (0%) | 0% | 171.0 | 153,720 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 169.71 per share. | 19 Feb 2025 | 535 | 71,356 (0%) | 0% | 169.7 | 90,795 | Common Stock |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 169.71 per share. | 19 Feb 2025 | 2,936 | 141,181 (0%) | 0% | 169.7 | 498,269 | Common Stock |
| Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 169.71 per share. | 19 Feb 2025 | 1,031 | 21,046 (0%) | 0% | 169.7 | 174,971 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 169.71 per share. | 19 Feb 2025 | 99 | 35,300 (0%) | 0% | 169.7 | 16,801 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 169.71 per share. | 19 Feb 2025 | 242 | 6,197 (0%) | 0% | 169.7 | 41,070 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 169.71 per share. | 19 Feb 2025 | 287 | 11,779 (0%) | 0% | 169.7 | 48,707 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 2,345 | 40,823 (0%) | 0% | 0 | Common Stock | |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 8,991 | 8,991 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 2,042 | 18,402 (0%) | 0% | 0 | Common Stock | |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,833 | 7,833 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | EVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 13,344 | 13,344 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | EVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 3,479 | 71,891 (0%) | 0% | 0 | Common Stock | |
| James E. Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 18,149 | 144,117 (0%) | 0% | 0 | Common Stock | |
| James E. Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 69,633 | 69,633 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 17,403 | 17,403 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 4,538 | 22,077 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 454 | 35,399 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 1,738 | 1,738 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Mark Delaney | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,960 | 6,960 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Mark Delaney | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 1,815 | 6,439 (0%) | 0% | 0 | Common Stock | |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 8,702 | 8,702 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 2,269 | 12,066 (0%) | 0% | 0 | Common Stock | |
| Vicky Gregg | Director | Sale of securities on an exchange or to another person at price $ 164.57 per share. | 05 Feb 2025 | 1,250 | 16,867 (0%) | 0% | 164.6 | 205,710 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 164.30 per share. | 05 Feb 2025 | 403 | 4,624 (0%) | 0% | 164.3 | 66,214 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | 29 Jan 2025 | 57 | 16,345 (0%) | 0% | 158.0 | 9,008 | Common Stock | |
| Vicky Gregg | Director | 29 Jan 2025 | 72 | 18,117 (0%) | 0% | 158.0 | 11,379 | Common Stock | |
| Sam A. Samad | Executive Vice President & CFO | 29 Jan 2025 | 35 | 17,539 (0%) | 0% | 158.0 | 5,531 | Common Stock | |
| Mark Delaney | SVP & Chief Commercial Officer | 29 Jan 2025 | 4 | 5,027 (0%) | 0% | 158 | 632 | Common Stock | |
| Karthik Kuppusamy | SVP, Clinical Solutions | 29 Jan 2025 | 12 | 9,780 (0%) | 0% | 158 | 1,896 | Common Stock | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 281 | 16,081 | - | - | Phantom Stock Units | |
| Wright L. Lassiter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 190 | 190 | - | - | Phantom Stock Units | |
| Michael E. Prevoznik | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 35,146 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 163.15 per share. | 29 Nov 2024 | 32,137 | 38,478 (0%) | 0% | 163.1 | 5,243,065 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 162.26 per share. | 29 Nov 2024 | 3,009 | 70,615 (0%) | 0% | 162.3 | 488,237 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.63 per share. | 29 Nov 2024 | 35,146 | 73,624 (0%) | 0% | 86.6 | 3,044,698 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2024 | 33,103 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 163.13 per share. | 27 Nov 2024 | 28,300 | 68,412 (0%) | 0% | 163.1 | 4,616,709 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 162.14 per share. | 27 Nov 2024 | 4,803 | 96,712 (0%) | 0% | 162.1 | 778,775 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.57 per share. | 27 Nov 2024 | 33,103 | 101,515 (0%) | 0% | 103.6 | 3,428,478 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 10,120 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Sale of securities on an exchange or to another person at price $ 154.74 per share. | 06 Nov 2024 | 4,135 | 45,061 (0%) | 0% | 154.7 | 639,833 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Sale of securities on an exchange or to another person at price $ 153.98 per share. | 06 Nov 2024 | 2,400 | 49,196 (0%) | 0% | 154.0 | 369,559 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Sale of securities on an exchange or to another person at price $ 152.70 per share. | 06 Nov 2024 | 2,100 | 51,596 (0%) | 0% | 152.7 | 320,676 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.51 per share. | 06 Nov 2024 | 10,120 | 53,696 (0%) | 0% | 66.5 | 673,081 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.17 per share. | 06 Nov 2024 | 8,635 | 43,576 (0%) | 0% | 71.2 | 614,553 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 8,635 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Sale of securities on an exchange or to another person at price $ 154.74 per share. | 06 Nov 2024 | 5,189 | 34,941 (0%) | 0% | 154.7 | 802,958 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Sale of securities on an exchange or to another person at price $ 154.03 per share. | 06 Nov 2024 | 2,331 | 40,130 (0%) | 0% | 154.0 | 359,046 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Sale of securities on an exchange or to another person at price $ 152.71 per share. | 06 Nov 2024 | 2,600 | 42,461 (0%) | 0% | 152.7 | 397,050 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Sale of securities on an exchange or to another person at price $ 156.92 per share. | 28 Oct 2024 | 1,775 | 9,734 (0%) | 0% | 156.9 | 278,525 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | 21 Oct 2024 | 60 | 16,258 (0%) | 0% | 149.4 | 8,962 | Common Stock | |
| Vicky Gregg | Director | 21 Oct 2024 | 76 | 18,045 (0%) | 0% | 149.4 | 11,352 | Common Stock | |
| Sam A. Samad | Executive Vice President & CFO | 21 Oct 2024 | 37 | 17,504 (0%) | 0% | 149.4 | 5,527 | Common Stock | |
| Mark Delaney | SVP & Chief Commercial Officer | 21 Oct 2024 | 4 | 5,023 (0%) | 0% | 149.5 | 598 | Common Stock | |
| Karthik Kuppusamy | SVP, Clinical Solutions | 21 Oct 2024 | 21 | 11,509 (0%) | 0% | 149.4 | 3,137 | Common Stock | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 275 | 15,720 | - | - | Phantom Stock Units | |
| Mark A. Gardner | SVP of Molecular Gen & Oncol | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.70 per share. | 24 Sep 2024 | 120 | 4,673 (0%) | 0% | 155.7 | 18,684 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 154.97 per share. | 29 Aug 2024 | 32,551 | 38,478 (0%) | 0% | 155.0 | 5,044,516 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2024 | 32,551 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael E. Prevoznik | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.79 per share. | 29 Aug 2024 | 32,551 | 71,029 (0%) | 0% | 95.8 | 3,118,223 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Sale of securities on an exchange or to another person at price $ 153.26 per share. | 28 Aug 2024 | 1,990 | 11,459 (0%) | 0% | 153.3 | 304,990 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 149.46 per share. | 14 Aug 2024 | 74 | 13,449 (0%) | 0% | 149.5 | 11,060 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | 24 Jul 2024 | 6 | 5,439 (0%) | 0% | 147 | 882 | Common Stock | |
| Mark Delaney | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 143.08 per share. | 24 Jul 2024 | 420 | 5,019 (0%) | 0% | 143.1 | 60,094 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | 22 Jul 2024 | 60 | 16,162 (0%) | 0% | 147.0 | 8,818 | Common Stock | |
| Vicky Gregg | Director | 22 Jul 2024 | 77 | 17,969 (0%) | 0% | 147.0 | 11,317 | Common Stock | |
| Sam A. Samad | Executive Vice President & CFO | 22 Jul 2024 | 21 | 17,467 (0%) | 0% | 147.0 | 3,086 | Common Stock | |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22 Jul 2024 | 31 | 13,511 (0%) | 0% | 147.0 | 4,556 | Common Stock | |
| Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.65 per share. | 16 Jul 2024 | 3,910 | 17,446 (0%) | 0% | 142.7 | 557,762 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 308 | 15,367 | - | - | Phantom Stock Units | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 27,798 (0%) | 0% | 0 | Common Stock | |
| Timothy L. Main | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 25,094 (0%) | 0% | 0 | Common Stock | |
| Denise M. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 9,490 (0%) | 0% | 0 | Common Stock | |
| Gary M. Pfeiffer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 28,916 (0%) | 0% | 0 | Common Stock | |
| Vicky Gregg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 17,892 (0%) | 0% | 0 | Common Stock | |
| Luis A. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 2,851 (0%) | 0% | 0 | Common Stock | |
| Wright L. Lassiter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 7,709 (0%) | 0% | 0 | Common Stock | |
| Tracey C. Doi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 5,183 (0%) | 0% | 0 | Common Stock | |
| Robert B. Carter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 1,482 | 1,482 (0%) | 0% | 0 | Common Stock | |
| Karthik Kuppusamy | SVP, Clinical Solutions | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 29 Apr 2024 | 1,760 | 13,435 (0%) | 0% | 140 | 246,400 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 126.25 per share. | 22 Apr 2024 | 69 | 16,062 (0%) | 0% | 126.2 | 8,711 | Common Stock |
| Vicky Gregg | Director | Grant, award, or other acquisition of securities at price $ 126.25 per share. | 22 Apr 2024 | 81 | 16,410 (0%) | 0% | 126.2 | 10,226 | Common Stock |
| Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 126.25 per share. | 22 Apr 2024 | 24 | 21,356 (0%) | 0% | 126.3 | 3,030 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 126.24 per share. | 22 Apr 2024 | 45 | 15,195 (0%) | 0% | 126.2 | 5,681 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 311 | 14,972 | - | - | Phantom Stock Units | |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.11 per share. | 26 Mar 2024 | 114 | 15,981 (0%) | 0% | 128.1 | 14,605 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.11 per share. | 26 Mar 2024 | 170 | 5,433 (0%) | 0% | 128.1 | 21,779 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 405 | 44,545 (0%) | 0% | 126.4 | 51,176 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 456 | 44,089 (0%) | 0% | 126.4 | 57,620 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 125.88 per share. | 28 Feb 2024 | 5,611 | 38,478 (0%) | 0% | 125.9 | 706,313 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 228 | 16,187 (0%) | 0% | 126.4 | 28,810 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 105 | 16,082 (0%) | 0% | 126.4 | 13,268 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 125.88 per share. | 28 Feb 2024 | 1,187 | 68,412 (0%) | 0% | 125.9 | 149,420 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 644 | 75,713 (0%) | 0% | 126.4 | 81,376 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 557 | 75,156 (0%) | 0% | 126.4 | 70,383 | Common Stock |
| Catherine T. Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 126.57 per share. | 28 Feb 2024 | 5,557 | 69,599 (0%) | 0% | 126.6 | 703,349 | Common Stock |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 3,216 | 127,772 (0%) | 0% | 126.4 | 406,374 | Common Stock |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 1,804 | 125,968 (0%) | 0% | 126.4 | 227,953 | Common Stock |
| Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 656 | 21,332 (0%) | 0% | 126.4 | 82,892 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.37 per share. | 28 Feb 2024 | 57 | 34,930 (0%) | 0% | 126.4 | 7,203 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.37 per share. | 28 Feb 2024 | 52 | 34,987 (0%) | 0% | 126.4 | 6,571 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 225 | 5,603 (0%) | 0% | 126.4 | 28,431 | Common Stock |
| Mark A. Gardner | SVP of Molecular Gen & Oncol | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 262 | 4,793 (0%) | 0% | 126.4 | 33,106 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.35 per share. | 28 Feb 2024 | 68 | 15,124 (0%) | 0% | 126.4 | 8,592 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.36 per share. | 28 Feb 2024 | 205 | 15,192 (0%) | 0% | 126.4 | 25,904 | Common Stock |
| T. Catherine Doherty | EVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 125.02 per share. | 23 Feb 2024 | 9,314 | 80,114 (0%) | 0% | 125.0 | 1,164,436 | Common Stock |
| Doherty Catherine T. | EVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 23 Feb 2024 | 3,757 | 76,357 (0%) | 0% | 125.0 | 469,700 | Common Stock |
| E. Davis James | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 23 Feb 2024 | 6,525 | 130,988 (0%) | 0% | 125.0 | 815,756 | Common Stock |
| Gregg Vicky | Director | Sale of securities on an exchange or to another person at price $ 126.64 per share. | 23 Feb 2024 | 2,500 | 16,329 (0%) | 0% | 126.6 | 316,597 | Common Stock |
| Kuppusamy Karthik | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 23 Feb 2024 | 619 | 15,397 (0%) | 0% | 125.0 | 77,387 | Common Stock |
| Michael Prevoznik E. | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 23 Feb 2024 | 2,825 | 44,950 (0%) | 0% | 125.0 | 353,182 | Common Stock |
| Prevoznik Michael E. | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 125.02 per share. | 23 Feb 2024 | 7,569 | 47,775 (0%) | 0% | 125.0 | 946,276 | Common Stock |
| Plewman Patrick | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 125.02 per share. | 23 Feb 2024 | 2,388 | 17,284 (0%) | 0% | 125.0 | 298,548 | Common Stock |
| Michael Deppe J. | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 125.02 per share. | 23 Feb 2024 | 1,689 | 35,670 (0%) | 0% | 125.0 | 211,159 | Common Stock |
| Davis E. James | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 125.02 per share. | 23 Feb 2024 | 13,390 | 137,513 (0%) | 0% | 125.0 | 1,674,018 | Common Stock |
| Plewman Patrick | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 23 Feb 2024 | 869 | 16,415 (0%) | 0% | 125.0 | 108,642 | Common Stock |
| Kuppusamy Karthik | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 125.02 per share. | 23 Feb 2024 | 2,039 | 16,016 (0%) | 0% | 125.0 | 254,916 | Common Stock |
| J. Michael Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 23 Feb 2024 | 631 | 35,039 (0%) | 0% | 125.0 | 78,888 | Common Stock |
| Prevoznik E. Michael | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 126.14 per share. | 21 Feb 2024 | 661 | 40,206 (0%) | 0% | 126.1 | 83,379 | Common Stock |
| Prevoznik E. Michael | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 21 Feb 2024 | 407 | 40,867 (0%) | 0% | 125.0 | 50,883 | Common Stock |
| E. Davis James | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 21 Feb 2024 | 762 | 124,123 (0%) | 0% | 125.0 | 95,265 | Common Stock |
| J. Michael Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 21 Feb 2024 | 89 | 33,981 (0%) | 0% | 125.0 | 11,127 | Common Stock |
| Kuppusamy Karthik | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 21 Feb 2024 | 102 | 13,977 (0%) | 0% | 125.0 | 12,752 | Common Stock |
| T. Catherine Doherty | EVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 21 Feb 2024 | 493 | 71,621 (0%) | 0% | 125.0 | 61,635 | Common Stock |
| Plewman Patrick | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.02 per share. | 21 Feb 2024 | 139 | 14,896 (0%) | 0% | 125.0 | 17,378 | Common Stock |
| T. Catherine Doherty | EVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 126.14 per share. | 21 Feb 2024 | 821 | 70,800 (0%) | 0% | 126.1 | 103,561 | Common Stock |
| Kuppusamy Karthik | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 11,007 | 11,007 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Doherty T. Catherine | SVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 17,939 | 17,939 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Samad Sam A. | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 5,478 | 21,988 (0%) | 0% | 0 | Common Stock | |
| Kuppusamy Karthik | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 2,641 | 14,079 (0%) | 0% | 0 | Common Stock | |
| Michael Prevoznik E. | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 2,935 | 41,274 (0%) | 0% | 0 | Common Stock | |
| E. James Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 22,251 | 124,885 (0%) | 0% | 0 | Common Stock | |
| Delaney Mark | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 9,783 | 9,783 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Mark Delaney | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 2,348 | 5,828 (0%) | 0% | 0 | Common Stock | |
| T. Doherty Catherine | SVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 4,304 | 72,114 (0%) | 0% | 0 | Common Stock | |
| Gardner A. Mark | SVP of Molecular Gen & Oncol | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 9,376 | 9,376 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 2,322 | 2,322 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Plewman Patrick | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 10,190 | 10,190 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 2,446 | 15,035 (0%) | 0% | 0 | Common Stock | |
| Samad A. Sam | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 22,835 | 22,835 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 12,231 | 12,231 | - | - | Non-Qualifed Stock Option (right to buy) | |
| J. Deppe Michael | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 558 | 34,070 (0%) | 0% | 0 | Common Stock | |
| A. Mark Gardner | SVP of Molecular Gen & Oncol | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 2,250 | 5,055 (0%) | 0% | 0 | Common Stock | |
| James E. Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 92,779 | 92,779 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Kuppusamy Karthik | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 129.31 per share. | 31 Jan 2024 | 29 | 11,438 (0%) | 0% | 129.3 | 3,750 | Common Stock |
| Samad A. Sam | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 129.35 per share. | 31 Jan 2024 | 17 | 16,510 (0%) | 0% | 129.4 | 2,199 | Common Stock |
| Plewman Patrick | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 129.32 per share. | 31 Jan 2024 | 50 | 12,589 (0%) | 0% | 129.3 | 6,466 | Common Stock |
| Vicky Gregg | Director | Grant, award, or other acquisition of securities at price $ 129.33 per share. | 31 Jan 2024 | 88 | 18,829 (0%) | 0% | 129.3 | 11,381 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 294 | 14,581 | - | - | Phantom Stock Units | |
| Michael E. Prevoznik | SVP & General Counsel | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2023 | 188 | 38,339 (0%) | 0% | 0 | Common Stock | |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 122.83 per share. | 23 Oct 2023 | 52 | 12,492 (0%) | 0% | 122.8 | 6,387 | Common Stock |
| Vicky Gregg | Director | Grant, award, or other acquisition of securities at price $ 122.86 per share. | 23 Oct 2023 | 92 | 18,741 (0%) | 0% | 122.9 | 11,303 | Common Stock |
| Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 122.89 per share. | 23 Oct 2023 | 18 | 16,493 (0%) | 0% | 122.9 | 2,212 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 122.87 per share. | 23 Oct 2023 | 30 | 11,358 (0%) | 0% | 122.9 | 3,686 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2023 | 344 | 14,205 | - | - | Phantom Stock Units | |
| Mark A. Gardner | SVP of Molecular Gen & Oncol | Payment of exercise price or tax liability using portion of securities received from the company at price $ 126.22 per share. | 25 Sep 2023 | 116 | 2,805 (0%) | 0% | 126.2 | 14,642 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 135.23 per share. | 15 Aug 2023 | 74 | 11,294 (0%) | 0% | 135.2 | 10,007 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 144.59 per share. | 25 Jul 2023 | 44 | 12,397 (0%) | 0% | 144.6 | 6,362 | Common Stock |
| Vicky Gregg | Director | Grant, award, or other acquisition of securities at price $ 144.59 per share. | 25 Jul 2023 | 78 | 18,649 (0%) | 0% | 144.6 | 11,278 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 144.60 per share. | 25 Jul 2023 | 25 | 11,355 (0%) | 0% | 144.6 | 3,615 | Common Stock |
| Sam A. Samad | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.18 per share. | 14 Jul 2023 | 3,909 | 16,475 (0%) | 0% | 140.2 | 547,964 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 297 | 13,793 | - | - | Phantom Stock Units | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 25,744 (0%) | 0% | 0 | Common Stock | |
| Timothy L. Main | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 23,612 (0%) | 0% | 0 | Common Stock | |
| Gail R. Wilensky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 20,506 (0%) | 0% | 0 | Common Stock | |
| Denise M. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 7,955 (0%) | 0% | 0 | Common Stock | |
| Gary M. Pfeiffer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 26,839 (0%) | 0% | 0 | Common Stock | |
| Vicky Gregg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 18,571 (0%) | 0% | 0 | Common Stock | |
| Luis A. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 1,369 (0%) | 0% | 0 | Common Stock | |
| Wright L. Lassiter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 6,092 (0%) | 0% | 0 | Common Stock | |
| Tracey C. Doi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 1,369 | 3,621 (0%) | 0% | 0 | Common Stock | |
| Patrick Plewman | SVP for Diagnostic Services | 24 Apr 2023 | 44 | 12,319 (0%) | 0% | 143.1 | 6,296 | Common Stock | |
| Vicky Gregg | Director | 24 Apr 2023 | 72 | 17,202 (0%) | 0% | 143.1 | 10,302 | Common Stock | |
| Karthik Kuppusamy | SVP, Clinical Solutions | 24 Apr 2023 | 25 | 11,295 (0%) | 0% | 143.1 | 3,577 | Common Stock | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 291 | 13,431 | - | - | Phantom Stock Units | |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.25 per share. | 24 Mar 2023 | 99 | 12,258 (0%) | 0% | 134.3 | 13,291 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.25 per share. | 24 Mar 2023 | 170 | 3,480 (0%) | 0% | 134.3 | 22,823 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 06 Mar 2023 | 3,841 | 43,281 (0%) | 0% | 147.9 | 567,930 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 140.55 per share. | 06 Mar 2023 | 4,754 | 38,527 (0%) | 0% | 140.6 | 668,175 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 147.86 per share. | 06 Mar 2023 | 8,595 | 47,122 (0%) | 0% | 147.9 | 1,270,857 | Common Stock |
| Stephen H. Rusckowski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 06 Mar 2023 | 38,604 | 389,597 (0%) | 0% | 147.9 | 5,707,987 | Common Stock |
| Stephen H. Rusckowski | Director | Grant, award, or other acquisition of securities at price $ 147.86 per share. | 06 Mar 2023 | 82,631 | 428,201 (0%) | 0% | 147.9 | 12,217,820 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 147.86 per share. | 06 Mar 2023 | 2,579 | 13,145 (0%) | 0% | 147.9 | 381,331 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 06 Mar 2023 | 799 | 12,357 (0%) | 0% | 147.9 | 118,140 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 140.55 per share. | 06 Mar 2023 | 5,307 | 67,810 (0%) | 0% | 140.6 | 745,899 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 06 Mar 2023 | 4,610 | 73,117 (0%) | 0% | 147.9 | 681,635 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 147.86 per share. | 06 Mar 2023 | 9,917 | 77,727 (0%) | 0% | 147.9 | 1,466,328 | Common Stock |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 06 Mar 2023 | 8,036 | 102,634 (0%) | 0% | 147.9 | 1,188,203 | Common Stock |
| James E. Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 147.86 per share. | 06 Mar 2023 | 15,204 | 110,670 (0%) | 0% | 147.9 | 2,248,063 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 06 Mar 2023 | 682 | 33,497 (0%) | 0% | 147.9 | 100,841 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 147.86 per share. | 06 Mar 2023 | 1,918 | 34,178 (0%) | 0% | 147.9 | 283,595 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 147.86 per share. | 06 Mar 2023 | 1,985 | 11,824 (0%) | 0% | 147.9 | 293,502 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 06 Mar 2023 | 583 | 11,241 (0%) | 0% | 147.9 | 86,202 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 140.63 per share. | 03 Mar 2023 | 717 | 67,810 (0%) | 0% | 140.6 | 100,832 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 138.54 per share. | 01 Mar 2023 | 593 | 38,527 (0%) | 0% | 138.5 | 82,154 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.69 per share. | 01 Mar 2023 | 320 | 39,120 (0%) | 0% | 140.7 | 45,021 | Common Stock |
| Stephen H. Rusckowski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.69 per share. | 01 Mar 2023 | 3,496 | 345,570 (0%) | 0% | 140.7 | 491,852 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.69 per share. | 01 Mar 2023 | 90 | 10,566 (0%) | 0% | 140.7 | 12,662 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.69 per share. | 01 Mar 2023 | 392 | 68,527 (0%) | 0% | 140.7 | 55,150 | Common Stock |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.69 per share. | 01 Mar 2023 | 1,292 | 95,466 (0%) | 0% | 140.7 | 181,771 | Common Stock |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.69 per share. | 01 Mar 2023 | 68 | 32,260 (0%) | 0% | 140.7 | 9,567 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 140.69 per share. | 01 Mar 2023 | 65 | 9,839 (0%) | 0% | 140.7 | 9,145 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 23 Feb 2023 | 811 | 38,413 (0%) | 0% | 147.9 | 119,914 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 9,653 | 9,653 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 141.42 per share. | 23 Feb 2023 | 1,415 | 39,440 (0%) | 0% | 141.4 | 200,109 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 2,442 | 40,855 (0%) | 0% | 0 | Common Stock | |
| Stephen H. Rusckowski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 20,059 | 349,066 (0%) | 0% | 0 | Common Stock | |
| Stephen H. Rusckowski | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 23 Feb 2023 | 5,826 | 329,007 (0%) | 0% | 147.9 | 861,432 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 23 Feb 2023 | 245 | 8,737 (0%) | 0% | 147.9 | 36,226 | Common Stock |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 7,584 | 7,584 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Patrick Plewman | SVP for Diagnostic Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 1,919 | 10,656 (0%) | 0% | 0 | Common Stock | |
| Catherine T. Doherty | SVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 15,167 | 15,167 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | SVP, Regional Businesses | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 3,838 | 70,609 (0%) | 0% | 0 | Common Stock | |
| Catherine T. Doherty | SVP, Regional Businesses | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 23 Feb 2023 | 962 | 66,771 (0%) | 0% | 147.9 | 142,241 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 141.42 per share. | 23 Feb 2023 | 1,690 | 68,919 (0%) | 0% | 141.4 | 239,000 | Common Stock |
| James E. Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 17,443 | 96,758 (0%) | 0% | 0 | Common Stock | |
| James E. Davis | Director, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 23 Feb 2023 | 1,473 | 79,315 (0%) | 0% | 147.9 | 217,798 | Common Stock |
| James E. Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 68,956 | 68,956 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 18,616 | 18,616 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Sam A. Samad | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 4,710 | 20,384 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 1,960 | 1,960 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 498 | 32,328 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | SVP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 23 Feb 2023 | 188 | 31,825 (0%) | 0% | 147.9 | 27,798 | Common Stock |
| Mark Delaney | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 1,919 | 3,650 (0%) | 0% | 0 | Common Stock | |
| Mark Delaney | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 7,584 | 7,584 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Mark A. Gardner | SVP of Molecular Gen & Oncol | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 7,584 | 7,584 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Mark A. Gardner | SVP of Molecular Gen & Oncol | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 1,919 | 2,921 (0%) | 0% | 0 | Common Stock | |
| Karthik Kuppusamy | SVP, Clinical Solutions | Payment of exercise price or tax liability using portion of securities received from the company at price $ 147.86 per share. | 23 Feb 2023 | 195 | 7,810 (0%) | 0% | 147.9 | 28,833 | Common Stock |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 8,270 | 8,270 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Karthik Kuppusamy | SVP, Clinical Solutions | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 2,094 | 9,904 (0%) | 0% | 0 | Common Stock | |
| Patrick Plewman | SVP for Diagnostic Services | 01 Feb 2023 | 27 | 8,982 (0%) | 0% | 146.7 | 3,962 | Common Stock | |
| Vicky Gregg | Director | 01 Feb 2023 | 64 | 17,130 (0%) | 0% | 146.8 | 9,392 | Common Stock | |
| Karthik Kuppusamy | SVP, Clinical Solutions | 01 Feb 2023 | 13 | 8,005 (0%) | 0% | 146.8 | 1,908 | Common Stock | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 267 | 13,081 | - | - | Phantom Stock Units | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 972 | 0 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 1,053 | 0 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.01 per share. | 01 Dec 2022 | 972 | 25,121 (0%) | 0% | 62.0 | 60,274 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.13 per share. | 01 Dec 2022 | 1,053 | 26,174 (0%) | 0% | 53.1 | 55,941 | Common Stock |
| Timothy M. Ring | Director | Sale of securities on an exchange or to another person at price $ 152.50 per share. | 01 Dec 2022 | 2,025 | 24,149 (0%) | 0% | 152.5 | 308,813 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 148.92 per share. | 28 Nov 2022 | 17,358 | 91,140 (0%) | 0% | 148.9 | 2,584,872 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Nov 2022 | 40,765 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | SVP, Regional Businesses | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.63 per share. | 28 Nov 2022 | 40,765 | 108,498 (0%) | 0% | 86.6 | 3,531,472 | Common Stock |
| Catherine T. Doherty | SVP, Regional Businesses | Sale of securities on an exchange or to another person at price $ 149.37 per share. | 28 Nov 2022 | 23,407 | 67,733 (0%) | 0% | 149.4 | 3,496,390 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 60.78 per share. | 01 Nov 2022 | 1,371 | 25,564 (0%) | 0% | 60.8 | 83,336 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.23 per share. | 01 Nov 2022 | 260 | 24,193 (0%) | 0% | 61.2 | 15,919 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 369 | 972 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 1,371 | 0 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2022 | 260 | 0 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Sale of securities on an exchange or to another person at price $ 144.06 per share. | 01 Nov 2022 | 2,000 | 24,149 (0%) | 0% | 144.1 | 288,120 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 62.01 per share. | 01 Nov 2022 | 369 | 25,933 (0%) | 0% | 62.0 | 22,882 | Common Stock |
| James E. Davis | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 13,980 | 80,788 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.17 per share. | 26 Oct 2022 | 9,126 | 41,132 (0%) | 0% | 52.2 | 476,058 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2022 | 6,371 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2022 | 9,126 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Sale of securities on an exchange or to another person at price $ 145.00 per share. | 26 Oct 2022 | 15,497 | 32,013 (0%) | 0% | 145 | 2,247,065 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.12 per share. | 26 Oct 2022 | 6,371 | 47,503 (0%) | 0% | 56.1 | 357,541 | Common Stock |
| Vicky Gregg | Director | 19 Oct 2022 | 74 | 17,066 (0%) | 0% | 127.7 | 9,447 | Common Stock | |
| Timothy M. Ring | Director | Sale of securities on an exchange or to another person at price $ 123.39 per share. | 03 Oct 2022 | 2,000 | 23,933 (0%) | 0% | 123.4 | 246,780 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 333 | 12,748 | - | - | Phantom Stock Units | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Oct 2022 | 2,000 | 260 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.22 per share. | 03 Oct 2022 | 2,000 | 25,933 (0%) | 0% | 61.2 | 122,450 | Common Stock |
| Timothy M. Ring | Director | Sale of securities on an exchange or to another person at price $ 125.02 per share. | 01 Sep 2022 | 2,000 | 23,933 (0%) | 0% | 125.0 | 250,040 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2022 | 2,000 | 2,260 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.22 per share. | 01 Sep 2022 | 2,000 | 25,933 (0%) | 0% | 61.2 | 122,450 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 1,851 | 4,260 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2022 | 149 | 0 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Sale of securities on an exchange or to another person at price $ 136.04 per share. | 01 Aug 2022 | 2,000 | 23,933 (0%) | 0% | 136.0 | 272,080 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.22 per share. | 01 Aug 2022 | 1,851 | 25,933 (0%) | 0% | 61.2 | 113,327 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.25 per share. | 01 Aug 2022 | 149 | 24,082 (0%) | 0% | 56.2 | 8,381 | Common Stock |
| Vicky Gregg | Director | 20 Jul 2022 | 70 | 16,992 (0%) | 0% | 134.5 | 9,413 | Common Stock | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.25 per share. | 01 Jul 2022 | 1,010 | 24,943 (0%) | 0% | 56.3 | 56,813 | Common Stock |
| Timothy M. Ring | Director | Sale of securities on an exchange or to another person at price $ 133.47 per share. | 01 Jul 2022 | 2,000 | 23,933 (0%) | 0% | 133.5 | 266,940 | Common Stock |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 1,010 | 149 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 990 | 0 | - | - | Stock Options (Right to Buy) | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 308 | 12,355 | - | - | Phantom Stock Units | |
| Timothy M. Ring | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 58.68 per share. | 01 Jul 2022 | 990 | 25,933 (0%) | 0% | 58.7 | 58,098 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.58 per share. | 25 May 2022 | 9,823 | 339,864 (0%) | 0% | 140.6 | 1,380,927 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 141.35 per share. | 25 May 2022 | 4,131 | 335,733 (0%) | 0% | 141.3 | 583,909 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.60 per share. | 25 May 2022 | 6,821 | 338,049 (0%) | 0% | 140.6 | 959,046 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.57 per share. | 25 May 2022 | 10,037 | 344,870 (0%) | 0% | 103.6 | 1,039,532 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 142.15 per share. | 25 May 2022 | 651 | 334,833 (0%) | 0% | 142.2 | 92,540 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 141.36 per share. | 25 May 2022 | 2,565 | 335,484 (0%) | 0% | 141.4 | 362,591 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 14,854 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.63 per share. | 25 May 2022 | 14,854 | 349,687 (0%) | 0% | 86.6 | 1,286,802 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 10,037 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 142.13 per share. | 25 May 2022 | 900 | 334,833 (0%) | 0% | 142.1 | 127,921 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2022 | 126,126 | 10,037 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.57 per share. | 23 May 2022 | 34,898 | 369,731 (0%) | 0% | 103.6 | 3,614,386 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.12 per share. | 23 May 2022 | 33,898 | 335,833 (0%) | 0% | 140.1 | 4,749,923 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 141.54 per share. | 23 May 2022 | 800 | 335,033 (0%) | 0% | 141.5 | 113,234 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 142.26 per share. | 23 May 2022 | 200 | 334,833 (0%) | 0% | 142.3 | 28,451 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.63 per share. | 23 May 2022 | 42,568 | 377,401 (0%) | 0% | 86.6 | 3,687,666 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.12 per share. | 23 May 2022 | 41,268 | 336,133 (0%) | 0% | 140.1 | 5,782,431 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 141.51 per share. | 23 May 2022 | 1,000 | 335,133 (0%) | 0% | 141.5 | 141,509 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 142.24 per share. | 23 May 2022 | 300 | 334,833 (0%) | 0% | 142.2 | 42,672 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 103.57 per share. | 23 May 2022 | 126,126 | 460,959 (0%) | 0% | 103.6 | 13,062,870 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.12 per share. | 23 May 2022 | 126,126 | 334,833 (0%) | 0% | 140.1 | 17,672,775 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.63 per share. | 23 May 2022 | 156,282 | 491,115 (0%) | 0% | 86.6 | 13,538,710 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.12 per share. | 23 May 2022 | 156,282 | 334,833 (0%) | 0% | 140.1 | 21,898,546 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2022 | 34,898 | 136,163 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2022 | 42,568 | 171,136 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2022 | 156,282 | 14,854 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 1,292 | 23,933 (0%) | 0% | 0 | Common Stock | |
| Timothy L. Main | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 1,292 | 22,243 (0%) | 0% | 0 | Common Stock | |
| Gail R. Wilensky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 1,292 | 19,137 (0%) | 0% | 0 | Common Stock | |
| Denise M. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 1,292 | 6,540 (0%) | 0% | 0 | Common Stock | |
| Gary M. Pfeiffer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 1,292 | 24,982 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 137.00 per share. | 18 May 2022 | 8 | 32,006 (0%) | 0% | 137 | 1,096 | Common Stock |
| Wright L. Lassiter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 1,292 | 4,633 (0%) | 0% | 0 | Common Stock | |
| Tracey C. Doi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 1,292 | 2,209 (0%) | 0% | 0 | Common Stock | |
| Michael E. Prevoznik | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.51 per share. | 17 May 2022 | 50,604 | 89,828 (0%) | 0% | 66.5 | 3,365,672 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2022 | 50,604 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 139.97 per share. | 17 May 2022 | 50,604 | 39,224 (0%) | 0% | 140.0 | 7,082,991 | Common Stock |
| Vicky Gregg | Director | 18 Apr 2022 | 61 | 15,630 (0%) | 0% | 134.9 | 8,228 | Common Stock | |
| Vicky Gregg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2022 | 1,292 | 16,922 (0%) | 0% | 0 | Common Stock | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 306 | 11,991 | - | - | Phantom Stock Units | |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 135.21 per share. | 07 Mar 2022 | 6,228 | 39,224 (0%) | 0% | 135.2 | 842,088 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 130.09 per share. | 07 Mar 2022 | 11,544 | 50,768 (0%) | 0% | 130.1 | 1,501,759 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 07 Mar 2022 | 5,316 | 45,452 (0%) | 0% | 130.1 | 691,558 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 130.09 per share. | 07 Mar 2022 | 70,184 | 367,403 (0%) | 0% | 130.1 | 9,130,237 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 07 Mar 2022 | 32,570 | 334,833 (0%) | 0% | 130.1 | 4,237,031 | Common Stock |
| Mark J. Guinan | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 07 Mar 2022 | 10,475 | 98,981 (0%) | 0% | 130.1 | 1,362,693 | Common Stock |
| Mark J. Guinan | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 130.09 per share. | 07 Mar 2022 | 20,780 | 109,456 (0%) | 0% | 130.1 | 2,703,270 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Sale of securities on an exchange or to another person at price $ 135.21 per share. | 07 Mar 2022 | 7,032 | 67,733 (0%) | 0% | 135.2 | 950,797 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 07 Mar 2022 | 6,360 | 74,765 (0%) | 0% | 130.1 | 827,372 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Grant, award, or other acquisition of securities at price $ 130.09 per share. | 07 Mar 2022 | 13,392 | 81,125 (0%) | 0% | 130.1 | 1,742,165 | Common Stock |
| James E. Davis | EVP-Gen. Diagnostics/CEO Elect | Grant, award, or other acquisition of securities at price $ 130.09 per share. | 07 Mar 2022 | 19,856 | 77,138 (0%) | 0% | 130.1 | 2,583,067 | Common Stock |
| James E. Davis | EVP-Gen. Diagnostics/CEO Elect | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 07 Mar 2022 | 10,330 | 66,808 (0%) | 0% | 130.1 | 1,343,830 | Common Stock |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Grant, award, or other acquisition of securities at price $ 130.09 per share. | 07 Mar 2022 | 16,162 | 56,338 (0%) | 0% | 130.1 | 2,102,515 | Common Stock |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 07 Mar 2022 | 7,947 | 48,391 (0%) | 0% | 130.1 | 1,033,825 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 07 Mar 2022 | 79 | 32,011 (0%) | 0% | 130.1 | 10,277 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 130.09 per share. | 07 Mar 2022 | 2,310 | 32,718 (0%) | 0% | 130.1 | 300,508 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 07 Mar 2022 | 835 | 31,883 (0%) | 0% | 130.1 | 108,625 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 130.09 per share. | 07 Mar 2022 | 206 | 32,089 (0%) | 0% | 130.1 | 26,799 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 130.00 per share. | 28 Feb 2022 | 661 | 39,224 (0%) | 0% | 130 | 85,930 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 13,301 | 13,301 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 2,741 | 39,885 (0%) | 0% | 0 | Common Stock | |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 126.26 per share. | 24 Feb 2022 | 1,669 | 37,144 (0%) | 0% | 126.3 | 210,728 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 22,510 | 297,219 (0%) | 0% | 0 | Common Stock | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 109,317 | 109,317 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Mark J. Guinan | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 2,251 | 88,676 (0%) | 0% | 0 | Common Stock | |
| Mark J. Guinan | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 10,932 | 10,932 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 3,328 | 67,733 (0%) | 0% | 0 | Common Stock | |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 16,155 | 16,155 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Sale of securities on an exchange or to another person at price $ 126.26 per share. | 24 Feb 2022 | 2,750 | 64,405 (0%) | 0% | 126.3 | 347,215 | Common Stock |
| James E. Davis | EVP-Gen. Diagnostics/CEO Elect | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 9,787 | 57,282 (0%) | 0% | 0 | Common Stock | |
| James E. Davis | EVP-Gen. Diagnostics/CEO Elect | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 47,529 | 47,529 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 3,915 | 32,346 (0%) | 0% | 0 | Common Stock | |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 19,009 | 19,009 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 7,830 | 40,176 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 2,654 | 2,654 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 3,132 | 30,408 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 549 | 27,276 (0%) | 0% | 0 | Common Stock | |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 23 Feb 2022 | 933 | 39,219 (0%) | 0% | 130.1 | 121,374 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.23 per share. | 23 Feb 2022 | 406 | 38,813 (0%) | 0% | 130.2 | 52,873 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.23 per share. | 23 Feb 2022 | 2,255 | 274,709 (0%) | 0% | 130.2 | 293,669 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 23 Feb 2022 | 7,463 | 276,964 (0%) | 0% | 130.1 | 970,862 | Common Stock |
| Mark J. Guinan | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 23 Feb 2022 | 1,673 | 87,119 (0%) | 0% | 130.1 | 217,641 | Common Stock |
| Mark J. Guinan | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.23 per share. | 23 Feb 2022 | 694 | 86,425 (0%) | 0% | 130.2 | 90,380 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.23 per share. | 23 Feb 2022 | 492 | 67,155 (0%) | 0% | 130.2 | 64,073 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 23 Feb 2022 | 1,082 | 67,647 (0%) | 0% | 130.1 | 140,757 | Common Stock |
| James E. Davis | EVP-Gen. Diagnostics/CEO Elect | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.23 per share. | 23 Feb 2022 | 724 | 47,495 (0%) | 0% | 130.2 | 94,287 | Common Stock |
| James E. Davis | EVP-Gen. Diagnostics/CEO Elect | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 23 Feb 2022 | 1,712 | 48,219 (0%) | 0% | 130.1 | 222,714 | Common Stock |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.23 per share. | 23 Feb 2022 | 609 | 28,431 (0%) | 0% | 130.2 | 79,310 | Common Stock |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 23 Feb 2022 | 1,368 | 28,882 (0%) | 0% | 130.1 | 177,963 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.23 per share. | 23 Feb 2022 | 94 | 26,727 (0%) | 0% | 130.2 | 12,242 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 130.09 per share. | 23 Feb 2022 | 219 | 26,640 (0%) | 0% | 130.1 | 28,490 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 247 | 11,631 | - | - | Phantom Stock Units | |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.79 per share. | 29 Nov 2021 | 37,565 | 106,294 (0%) | 0% | 95.8 | 3,598,539 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2021 | 37,565 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Sale of securities on an exchange or to another person at price $ 157.53 per share. | 29 Nov 2021 | 14,575 | 68,729 (0%) | 0% | 157.5 | 2,296,043 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Sale of securities on an exchange or to another person at price $ 156.85 per share. | 29 Nov 2021 | 15,908 | 83,304 (0%) | 0% | 156.9 | 2,495,249 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Sale of securities on an exchange or to another person at price $ 155.77 per share. | 29 Nov 2021 | 3,532 | 99,212 (0%) | 0% | 155.8 | 550,194 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Sale of securities on an exchange or to another person at price $ 154.79 per share. | 29 Nov 2021 | 3,250 | 102,744 (0%) | 0% | 154.8 | 503,074 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Sale of securities on an exchange or to another person at price $ 153.38 per share. | 29 Nov 2021 | 300 | 105,994 (0%) | 0% | 153.4 | 46,015 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 288 | 11,336 | - | - | Phantom Stock Units | |
| Tracey C. Doi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2021 | 905 | 905 (0%) | 0% | 0 | Common Stock | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.14 per share. | 28 Jul 2021 | 139,751 | 284,427 (0%) | 0% | 140.1 | 19,584,845 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2021 | 4,193 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2021 | 5,300 | 4,193 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2021 | 139,751 | 9,493 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 141.22 per share. | 28 Jul 2021 | 4,193 | 284,427 (0%) | 0% | 141.2 | 592,119 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.79 per share. | 28 Jul 2021 | 4,193 | 288,620 (0%) | 0% | 95.8 | 401,668 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.59 per share. | 28 Jul 2021 | 5,300 | 284,427 (0%) | 0% | 140.6 | 745,132 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.80 per share. | 28 Jul 2021 | 5,300 | 289,727 (0%) | 0% | 95.8 | 507,714 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.79 per share. | 28 Jul 2021 | 139,751 | 424,178 (0%) | 0% | 95.8 | 13,387,447 | Common Stock |
| Gail R. Wilensky | Director | Sale of securities on an exchange or to another person at price $ 139.32 per share. | 27 Jul 2021 | 6,111 | 17,845 (0%) | 0% | 139.3 | 851,403 | Common Stock |
| Gail R. Wilensky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 6,111 | 0 | - | - | Stock Options (Right to Buy) | |
| Gail R. Wilensky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 6,111 | 0 | - | - | Stock Options (Right to Buy) | |
| Gail R. Wilensky | Director | Sale of securities on an exchange or to another person at price $ 139.27 per share. | 27 Jul 2021 | 6,111 | 17,845 (0%) | 0% | 139.3 | 851,067 | Common Stock |
| Gail R. Wilensky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.23 per share. | 27 Jul 2021 | 6,111 | 23,956 (0%) | 0% | 61.2 | 374,146 | Common Stock |
| Gail R. Wilensky | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 57.57 per share. | 27 Jul 2021 | 6,111 | 23,956 (0%) | 0% | 57.6 | 351,780 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.79 per share. | 26 Jul 2021 | 32,788 | 317,215 (0%) | 0% | 95.8 | 3,140,926 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 95.79 per share. | 26 Jul 2021 | 5,813 | 290,240 (0%) | 0% | 95.8 | 556,856 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.03 per share. | 26 Jul 2021 | 5,813 | 284,427 (0%) | 0% | 140.0 | 813,994 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 32,788 | 149,244 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Sale of securities on an exchange or to another person at price $ 140.01 per share. | 26 Jul 2021 | 32,788 | 284,427 (0%) | 0% | 140.0 | 4,590,550 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 5,813 | 182,032 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 313 | 10,999 | - | - | Phantom Stock Units | |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 1,363 | 22,234 (0%) | 0% | 0 | Common Stock | |
| Timothy L. Main | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 1,363 | 20,951 (0%) | 0% | 0 | Common Stock | |
| Gail R. Wilensky | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 1,363 | 17,845 (0%) | 0% | 0 | Common Stock | |
| Denise M. Morrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 1,363 | 5,206 (0%) | 0% | 0 | Common Stock | |
| Gary M. Pfeiffer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 1,363 | 23,265 (0%) | 0% | 0 | Common Stock | |
| Helen I. Torley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 1,363 | 6,260 (0%) | 0% | 0 | Common Stock | |
| Wright L. Lassiter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 1,363 | 3,281 (0%) | 0% | 0 | Common Stock | |
| Vicky Gregg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 1,363 | 15,400 (0%) | 0% | 0 | Common Stock | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 136.60 per share. | 18 May 2021 | 5 | 26,859 (0%) | 0% | 136.6 | 683 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Sale of securities on an exchange or to another person at price $ 139.96 per share. | 07 May 2021 | 8,536 | 68,729 (0%) | 0% | 140.0 | 1,194,724 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 137.00 per share. | 05 May 2021 | 44,939 | 40,152 (0%) | 0% | 137 | 6,156,643 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 44,939 | 0 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael E. Prevoznik | SVP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.17 per share. | 05 May 2021 | 44,939 | 85,091 (0%) | 0% | 71.2 | 3,198,309 | Common Stock |
| Timothy M. Ring | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 325 | 10,638 | - | - | Phantom Stock Units | |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 115.42 per share. | 09 Mar 2021 | 9,791 | 49,943 (0%) | 0% | 115.4 | 1,130,077 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.42 per share. | 09 Mar 2021 | 4,217 | 45,726 (0%) | 0% | 115.4 | 486,726 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 120.47 per share. | 09 Mar 2021 | 5,574 | 40,152 (0%) | 0% | 120.5 | 671,500 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.42 per share. | 09 Mar 2021 | 25,887 | 284,427 (0%) | 0% | 115.4 | 2,987,878 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 115.42 per share. | 09 Mar 2021 | 58,368 | 310,314 (0%) | 0% | 115.4 | 6,736,835 | Common Stock |
| Mark J. Guinan | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 115.42 per share. | 09 Mar 2021 | 17,322 | 95,195 (0%) | 0% | 115.4 | 1,999,305 | Common Stock |
| Mark J. Guinan | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.42 per share. | 09 Mar 2021 | 6,403 | 88,792 (0%) | 0% | 115.4 | 739,034 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.42 per share. | 09 Mar 2021 | 5,066 | 77,265 (0%) | 0% | 115.4 | 584,718 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Grant, award, or other acquisition of securities at price $ 115.42 per share. | 09 Mar 2021 | 11,299 | 82,331 (0%) | 0% | 115.4 | 1,304,131 | Common Stock |
| James E. Davis | EVP, General Diagnostics | Grant, award, or other acquisition of securities at price $ 115.42 per share. | 09 Mar 2021 | 16,570 | 58,265 (0%) | 0% | 115.4 | 1,912,509 | Common Stock |
| James E. Davis | EVP, General Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.42 per share. | 09 Mar 2021 | 8,334 | 49,931 (0%) | 0% | 115.4 | 961,910 | Common Stock |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.42 per share. | 09 Mar 2021 | 6,165 | 30,250 (0%) | 0% | 115.4 | 711,564 | Common Stock |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Grant, award, or other acquisition of securities at price $ 115.42 per share. | 09 Mar 2021 | 13,181 | 36,394 (0%) | 0% | 115.4 | 1,521,351 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.42 per share. | 09 Mar 2021 | 684 | 26,802 (0%) | 0% | 115.4 | 78,947 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 115.42 per share. | 09 Mar 2021 | 1,884 | 27,485 (0%) | 0% | 115.4 | 217,451 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 115.49 per share. | 25 Feb 2021 | 801 | 40,152 (0%) | 0% | 115.5 | 92,507 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.19 per share. | 23 Feb 2021 | 455 | 42,141 (0%) | 0% | 121.2 | 55,141 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 116.95 per share. | 23 Feb 2021 | 750 | 40,953 (0%) | 0% | 117.0 | 87,713 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 116.95 per share. | 23 Feb 2021 | 438 | 41,703 (0%) | 0% | 116.9 | 51,224 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.15 per share. | 23 Feb 2021 | 693 | 42,596 (0%) | 0% | 121.2 | 83,957 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.19 per share. | 23 Feb 2021 | 3,319 | 251,946 (0%) | 0% | 121.2 | 402,230 | Common Stock |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.15 per share. | 23 Feb 2021 | 4,033 | 255,265 (0%) | 0% | 121.2 | 488,598 | Common Stock |
| Mark J. Guinan | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.15 per share. | 23 Feb 2021 | 830 | 78,414 (0%) | 0% | 121.2 | 100,555 | Common Stock |
| Mark J. Guinan | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.19 per share. | 23 Feb 2021 | 541 | 77,873 (0%) | 0% | 121.2 | 65,564 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.19 per share. | 23 Feb 2021 | 524 | 71,032 (0%) | 0% | 121.2 | 63,504 | Common Stock |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.15 per share. | 23 Feb 2021 | 796 | 71,556 (0%) | 0% | 121.1 | 96,435 | Common Stock |
| James E. Davis | EVP, General Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.15 per share. | 23 Feb 2021 | 1,250 | 42,501 (0%) | 0% | 121.2 | 151,438 | Common Stock |
| James E. Davis | EVP, General Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.19 per share. | 23 Feb 2021 | 806 | 41,695 (0%) | 0% | 121.2 | 97,679 | Common Stock |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.15 per share. | 23 Feb 2021 | 1,017 | 23,824 (0%) | 0% | 121.2 | 123,210 | Common Stock |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.19 per share. | 23 Feb 2021 | 611 | 23,213 (0%) | 0% | 121.2 | 74,047 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.19 per share. | 23 Feb 2021 | 103 | 25,601 (0%) | 0% | 121.2 | 12,483 | Common Stock |
| Michael J. Deppe | VP, Corp. Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 121.15 per share. | 23 Feb 2021 | 159 | 25,704 (0%) | 0% | 121.2 | 19,263 | Common Stock |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 3,202 | 43,289 (0%) | 0% | 0 | Common Stock | |
| Michael E. Prevoznik | SVP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 17,958 | 17,958 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 120,901 | 120,901 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Stephen H. Rusckowski | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 21,551 | 259,298 (0%) | 0% | 0 | Common Stock | |
| Manuel O. Mendez Muniz | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 4,926 | 29,045 (0%) | 0% | 0 | Common Stock | |
| Manuel O. Mendez Muniz | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 27,633 | 27,633 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Mark J. Guinan | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 5,665 | 79,244 (0%) | 0% | 0 | Common Stock | |
| Mark J. Guinan | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 31,774 | 31,774 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 22,105 | 22,105 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Catherine T. Doherty | SVP, Group Exec. Clin. Fran. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 3,941 | 72,352 (0%) | 0% | 0 | Common Stock | |
| James E. Davis | EVP, General Diagnostics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 5,665 | 43,751 (0%) | 0% | 0 | Common Stock | |
| James E. Davis | EVP, General Diagnostics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 31,774 | 31,774 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 4,926 | 24,841 (0%) | 0% | 0 | Common Stock | |
| Carrie Eglinton Manner | SVP, Advanced Diagnostics | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 27,633 | 27,633 | - | - | Non-Qualifed Stock Option (right to buy) | |
| Michael J. Deppe | VP, Corp. Controller & CAO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 4,003 | 4,003 | - | - | Non-Qualifed Stock Option (right to buy) |